Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Drug company (FDA labeler)

Otsuka America Pharmaceutical, Inc.

NDC labeler code: 59148

What is a labeler?

The company whose name is on the package and in the FDA’s National Drug Code (NDC) Directory. It may make the medicine itself or sell medicine made by another company. The first part of every NDC code identifies the labeler.

Official FDA data only

Products, approvals and recalls come from the FDA (NDC Directory, Drugs@FDA, enforcement reports). Recalls are linked to this company by the NDC labeler code on the recalled product.

Questions about your medicine: ask your doctor or pharmacist. In an emergency, call 911.

At a glance

23Products (NDC)

Prescription medicines

FDA applications for these products

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
  • BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
ApprovedApplicationMedicineSponsor
July 24, 2026NDA218145 Centanafadine hydrochloride
SIMTRIYO
Otsuka Pharmaceutical Co Ltd
November 25, 2025BLA761434 Sibeprenlimab
VOYXACT
Otsuka Pharm Co Ltd
April 27, 2023NDA217006 Aripiprazole
ABILIFY ASIMTUFII
Otsuka
April 23, 2018NDA204441 Tolvaptan
JYNARQUE
Otsuka
July 10, 2015NDA205422 Brexpiprazole
REXULTI
Otsuka
October 29, 2010NDA021879 Dextromethorphan hydrobromide and quinidine sulfate
NUEDEXTA
Otsuka America Pharm
May 19, 2009NDA022275 Tolvaptan
SAMSCA
Otsuka
November 15, 2002NDA021436 Aripiprazole
ABILIFY
Otsuka

The sponsor is the company that holds the FDA application; it can differ from the labeler.

Recall timeline

2024

  1. April 9, 2024 · Class III · Ongoing · D-0466-2024 · Aripiprazole

    Cross Contamination with Other Products

    Abilify (aripiprazole), 5 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-007-13

  2. April 9, 2024 · Class III · Ongoing · D-0468-2024 · Aripiprazole

    Cross Contamination with Other Products

    Abilify (aripiprazole), 15 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-009-13

  3. April 9, 2024 · Class III · Ongoing · D-0467-2024 · Aripiprazole

    Cross Contamination with Other Products

    Abilify (aripiprazole), 10 mg tablets, packaged in a) 30 count bottles (NDC 59148-008-13) and b) 7 count blister packs (NDC 59148-008-95), RX only, Otsuka America Pharmaceutical, Inc.

  4. April 9, 2024 · Class III · Ongoing · D-0469-2024 · Aripiprazole

    Cross Contamination with Other Products

    Abilify (aripiprazole), 30 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-011-13

2012

  1. November 2, 2012 · Class II · Terminated · D-181-2013 · Aripiprazole

    CGMP Deviations: A drum of Abilify 30 mg Tablets rejected during the compression stage was not segregated from the other portion of the lot and was inadvertently shipped, packaged and distributed.

    ABILIFY (aripiprazole) Tablets, 30 mg, Rx only, Blister Pack of 100 tablets, Otsuka America Pharmaceutical Inc., Bristol-Myers Squibb NDC 59148-011-35

What do the recall classes mean?

Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).

Sources

  1. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  2. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026

FDA Enforcement Report search → · Report an error →